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ABSTRACT The ATP-binding cassette (ABC) genes
encode the largest family of transmembrane proteins.
ABC transporters translocate a wide variety of sub-
strates across membranes, but their physiological func-
tion is often incompletely understood. We describe a
new method to study the substrate spectrum of ABC
transporters: We incubate extracts of mouse urine with
membrane vesicles prepared from Spodoptera fru-
giperda Sf9 insect cells overproducing an ABC trans-
porter and determine the compounds transported into
the vesicles by LC/MS-based metabolomics. We illus-
trate the power of this simple “transportomics” ap-
proach using ABCC2, a protein present at sites of
uptake and elimination. We identified many new sub-
strates of ABCC2 in urine. These included glucu-
ronides of plant-derived xenobiotics, a class of com-
pounds to which humans are exposed on a daily basis.
Moreover, we show that the excretion of these com-
pounds in vivo depends on ABCC2: compared to wild-
type mice, the urinary excretion of several glucuronides
was increased up to 20-fold in Abcc2/ mice. Trans-
portomics has broad applicability, as it is not restricted
to urine and can be applied to other ATP-dependent
transport proteins as well.—Krumpochova, P., Sapthu,
S., Brouwers, J. F., de Haas, M., de Vos, R., Borst, P.,
van de Wetering, K. Transportomics: screening for
substrates of ABC transporters in body fluids using
vesicular transport assays. FASEB J. 26, 738–747 (2012).
www.fasebj.org
Key Words: metabolomics  LC/MS  phytoestrogens  knock-
out mice
ATP-binding cassette (ABC) transporters translocate
a wide variety of compounds through membranes at the
cost of ATP hydrolysis and have important roles in
human physiology, pathology, toxicology, pharmacol-
ogy, and disease (1). The functions of several ABC
transporters are incompletely understood, due to the
lack of knowledge about the substrates transported in
vivo.
ABCC2 [also known as multidrug resistance protein
2 (MRP2)] is a multispecific organic anion transporter,
and its substrates include several anionic drugs, bile
acids, and compounds conjugated to glutathione-, sul-
fate-, or glucuronic acid (i.e., phase II metabolites; refs.
1–4). ABCC2 has an apical subcellular localization and
is present in the body at sites of uptake and elimination,
such as enterocytes, hepatocytes, and cells of the prox-
imal tubules of the kidney (2). Its apical localization in
these cells allows ABCC2 to mediate hepatobiliary and
urinary elimination and to function as a barrier to
uptake from the gut lumen. ABCC2 function is missing
in patients with the Dubin-Johnson syndrome (5–8),
which leads to the impaired secretion of bilirubin-
glucuronides into bile and results in conjugated hyper-
bilirubinemia. Despite the identification of several
ABCC2 substrates, its substrate spectrum remains in-
completely characterized. Vesicular transport by ABC
transporters in inside-out vesicles is often used to
characterize their substrate specificity. This approach
has several drawbacks, however: one needs upfront
hypotheses about the compounds transported by the
specific ABC transporter; only one substrate can be
studied at a time; and expensive radioactive substrates
are usually required, and these are not available for all
compounds of interest.
We show here that these drawbacks can be bypassed
by putting the transporter-containing inside-out mem-
brane vesicles in body fluids and analyzing the vesicle
content by liquid chromatography/mass spectrometry
(LC/MS)-based metabolomics. This approach has al-
lowed us to obtain a comprehensive and relatively
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unbiased inventory of physiological substrates trans-
ported by ABCC2. This method has broad applicability
as it can be used to study other ATP-dependent mem-
brane transporters as well.
MATERIALS AND METHODS
Materials
Strata-X solid-phase extraction (SPE) cartridges (30 mg) and
the analytical Luna C18(2) columns (3 m, 1502.0 mm and
1504.6 mm) were from Phenomenex (Torrance, CA, USA).
The preparative Atlantis C18 column (10 m, 25019 mm)
was from Waters (Milford, MA, USA), and the capillary
Zorbax Eclipse Plus C18 column (3.5 m, 1500.5 mm) was
from Agilent (Santa Clara, CA, USA). Creatine phosphate
and creatine kinase were from Roche (Almere, The Nether-
lands). [35S]O4 and Ultima Gold liquid scintillation fluid
were from Perkin Elmer (Groningen, The Netherlands).
Multiscreen Hi Flow filter plates (MSFBNXB50) were from
Millipore (Amsterdam, The Netherlands). Acetonitrile and
methanol were from Biosolve (Valkenswaard, the Nether-
lands). All other chemicals and reagents were from Sigma-
Aldrich (St. Louis, MO, USA).
High-performance liquid chromatography (HPLC)
For the LC/MS experiments, the analytical HPLC system con-
sisted of two Series 200 micropumps (Perkin Elmer) and a
Quicksplit precolumn flow splitter (Analytical Scientific Instru-
ments, El Sobrante, CA, USA). Separations were performed on
a Zorbax Eclipse Plus C18 3.5 m column (1500.5 mm). The
Series 200 micropumps were operated to generate a flow of 200
l/min. The precolumn flow splitter was adjusted to get a flow
through the column of20 l/min. Total run time was 45 min,
and detection was by mass spectrometry (see below). The mobile
phases consisted of 5 mM ammonium acetate (mobile phase A)
and 5 mM ammonium acetate in 97.5% acetonitrile/2.5% water
(mobile phase B). Samples were separated using the following
gradient A:B (v/v): 0–5 min 93:7, 5–30 min 93:7 to 35:65, 30–31
min 35:65 to 0:100, 31–34 min 0:100, 34–35 min 0:100 to 93:7,
35–45 min 93:7. The enzymatically synthesized [35S]sulfo-phy-
toestrogen-glucuronides (see below) were purified on a Luna
C18(2) column (3 m, 1504.6 mm) with a flow rate of 600
l/min and detection with a radiomatic flow scintillation ana-
lyzer (Perkin Elmer). The mobile phases used were 10 mM
ammonium formate (pH 8.2; mobile phase A) and 10 mM
ammonium formate (pH 8.2) in 95% acetonitrile (mobile phase
B). The following gradient A:B (v/v) was used: 0–27 min 90:10
to 55:45, 27–27.1 min 0:100, 27.1–29 min 0:100, 29–32 min
0:100 to 90:10, and 32–40 min 90:10. The enzymatically synthe-
sized nonlabeled sulfo-phytoestrogen-glucuronides were HPLC
purified using the same gradient on an Atlantis C18 column (10
m, 25019 mm) at a flow rate of 15 ml/min and quantified
with a Waters 2487 UV detector. Peaks containing the gluc-
uronosyl-phytoestrogen-sulfates were manually collected based
on the UV chromatogram. Sulfo-enterodiol-glucuronide was
detected at 273 nm and sulfo-enterolactone-glucuronide at 274
nm. The concentrations of the enzymatically synthesized phy-
toestrogen-glucuronide stock solutions were determined as de-
scribed previously (9).
Mass spectrometry
Mass spectrometry was performed using an API4000Qtrap
(AB Sciex, Concord, ON, Canada) essentially as described
previously (9), with the following modifications due to the
transition to capillary LC: curtain gas (N2), 10 (arbitrary
units); CAD gas (N2), high; ion spray voltage, 4000 V;
source temperature, 350°C; gas flow 1 (N2), 19 psi; gas flow 2
(N2), 18 psi; decluster potential, 69 V; entrance potential,
10 V; collision energy, 39 V. Glucuronides are formed by
linking a glucuronic acid moiety to a compound via a
glycosidic bond (10). During tandem mass spectrometry, this
glycosidic bond is easily broken during collision-induced
dissociation (CID), which results in the loss of an uncharged
fragment of 176 Da, the glucuronate moiety, thereby gener-
ating charged ions with a mass to charge (m/z) ratio of
[M-H-176] if measured in the negative ion mode (11). In
short, during neutral loss scans, the first mass analyzer (first
quadrupole) sequentially determines the masses (m/z ratios)
of the molecules that enter the mass spectrometer. In the
second quadrupole, the molecules are fragmented by CID
and the mass of these fragments is determined in the second
mass analyzer (third quadrupole). This setup allows the
detection of compounds with a mass that is 176 Da lower in
the second than in the first mass analyzer. Neutral loss scans
are not very quantitative or sensitive and have a poor chro-
matographic resolution due to the long time needed to scan
from 200 to 800 Da. To overcome these limitations, we
focused on all the masses detected in control treated plasma
but absent after treatment with an enzyme that specifically
cleaves off glucuronic acid groups, -glucuronidase. These
masses were put in a multiple reaction monitoring (MRM)
list, adding up to 100 specific mass transitions in which 176 Da
was lost after CID (Supplemental Table S1). Each mass was
scanned for 15 ms, which resulted in shortened cycling time
(1.2 s), improved sensitivity, higher selectivity, and better
chromatographic resolution (9). In the chromatograms pre-
sented, each colored line represents a specific mass transition
in which 176 Da is lost. Quantification of the relative abun-
dance of specific glucuronides was performed by determining
the peak areas within the chromatograms and expressed as
arbitrary units (counts per second).
Enhanced product ion spectra of glucuronides found to be
differentially present in urine of wild-type and Abcc2/ mice
were made using information-dependent acquisition and
enhanced product ion generation, using a collision energy of
39 V and a collision energy spread of 10 V, and compared
to enzymatically synthesized phytoestrogen-glucuronide stan-
dards (see below) for identification.
Preparation of membrane vesicles and vesicular
transport assays
ATP-dependent transport into inside-out membrane vesicles
prepared from Sf9 cells overproducing human ABCC2 and
control Sf9 cells was measured using the rapid filtration
technique as described previously (9). Vesicular transport
experiments involving the use of urine as substrate matrix
were performed as follows: Abcc2/ urine was subjected to
solid-phase extraction (SPE) as described below and dissolved
in T/S buffer (50 mM Tris/250 mM sucrose, pH 7.4).
Membrane vesicles corresponding to 88 g of protein were
incubated in a total volume of 220 l containing an equiva-
lent of 2.2 l urine. At the indicated time points, 40 l of the
reaction mixture was filtered over a Millipore Hi Flow filter
plate and washed 4 with 200 l 150 mM ammonium acetate.
Compounds taken up by the vesicles were eluted from the
filters by pulling a solution of methanol/water (80:20)
through the filters (resulting in lysis of the vesicles) and
collection of the filtrate. The filtrate was evaporated till
dryness, and the pellet was dissolved in 40 l acetonitrile/
water (5:95) containing 5 mM ammonium acetate, of which
20 l was analyzed by LC/MS.
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Vesicular transport experiments using
HPLC-fractionated urine
To avoid competition from compounds transported by
ABCC2 with high affinity, we used in some experiments
HPLC-fractionated Abcc2/ urine. For these experiments, 10
ml urine of mice lacking ABCC2 was fractionated on a
preparative Atlantis C18 column with the gradient used for
the purification of the enzymatically synthesized phytoestro-
gens conjugated to sulfate and glucuronic acid. Fractions of 1
min were collected, freeze-dried, and dissolved in 2.5 ml T/S
buffer. Each fraction (10 l) was analyzed using the MRM
based glucuronide screen to identify the glucuronides pres-
ent in each fraction. The freeze-dried pellets of the fractions
were dissolved in 2.5 ml T/S buffer. The incubation mixture
of the vesicular transport experiments contained 10% of
these urine fractions.
Generation of phytoestrogen-glucuronide standards
Monoglucuronides of phytoestrogens were generated and puri-
fied as described previously (9). Phytoestrogen-glucuronides
were conjugated to sulfate by incubation with 1 mg of mouse
liver cytosol in 100 mM phosphate buffer (pH 7.4) containing 10
mM MgCl2, 2 M dithiothreitol, 100 M orthovanadate, and
200M 3-phosphoadenosine-5-phosphosulfate (PAPS) at 37°C
for 16 h. Compounds were extracted from the incubation mix as
described for the glucuronic acid conjugates. [35S]labeled phy-
toestrogens conjugated to a glucuronide and a sulfate were
prepared as described for the nonlabeled compounds with the
following modification: instead of PAPS, 20 mM ATP and 20Ci
[35S]O4 were added to the incubation mixture. The [
35S]O4-
labeled phytoestrogens conjugated to both a glucuronic acid
and a sulfate moiety were used in vesicular transport experi-
ments to determine the kinetics of their ABCC2-mediated
transport.
Animals
Abcc2/ mice have been described previously (12). All mice
used were on a 99% FVB genetic background, received food
and water ad libitum, and were housed in constant tempera-
ture rooms with a 12-h light-dark cycle. Mouse handling and
experimental procedures were approved by the Animal Ex-
periments Committee of The Netherlands Cancer Institute.
Collection and processing of urine samples of wild-type and
Abcc2/ mice
Urine was collected and processed as described previously
(9), with the following minor modifications: 5% of the urine
produced per mouse per 24 h was subjected to SPE on
Strata-X cartridges. Prior to analysis, the urine samples were
dissolved in 3750 l acetonitrile/water (5:95) containing 5
mM ammonium acetate. Of these diluted urine samples, 15
l was subsequently analyzed by LC/MS.
Gall bladder cannulation
Bile was collected by cannulation of the common bile duct of
5 mice/genotype, as described previously (13). Bile was
collected for 1 h and stored at 80°C till used. Of the 80-fold
diluted bile samples (acetonitrile/water, 5:95; 5 mM ammo-
nium acetate), 10 l was analyzed by LC/MS.
RESULTS
ABCC2 transports (unknown) glucuronides present in
Abcc2/ mouse urine in vesicular transport assays
ABCC2 present in vesicles should be able to transport
its substrates present in urine toward the vesicular
lumen. The compounds taken up can subsequently
be detected by LC/MS. Metabolomics is used to
determine metabolites in biological samples and
comes in 2 flavors: targeted and untargeted ap-
proaches. Untargeted metabolomics offers a higher
coverage of metabolites but is less sensitive than
targeted metabolomics. ABCC2 has been shown to
transport several glucuronic acid conjugates in vitro
(2); we therefore used a previously developed target-
ed-metabolomics screen for glucuronides to deter-
mine the compounds taken up in the vesicles (9). A
schematic representation of this approach is pre-
sented in Fig. 1, whereas Fig. 2 shows that this
approach worked: incubation of ABCC2-containing
vesicles in urine of female Abcc2/ mice in the
presence of ATP resulted in the accumulation of
many glucuronides inside the vesicles (Fig. 2A).
C
B
Figure 1. Schematic representation of the use of vesicular
transport assays to identify unknown ABCC2 substrates in body
fluids. A) ABCC2-containing vesicles are incubated with an extract
of a body fluid (e.g., urine) in the presence of ATP. Under these
conditions, ABCC2 will transport the ABCC2 substrates present in
this fluid into the vesicles. B) Analysis of the content of the vesicles
by LC/MS shows which compounds are present inside the ABCC2-
containing vesicles. C, D) Control vesicles that do not contain
ABCC2 are used to determine background transport of the various
compounds present in the body fluid. Compounds found in
ABCC2-containing vesicles (B), but nearly absent in control vesicles
(D), are considered ABCC2 substrates.
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Control vesicles incubated under the same condi-
tions contained virtually no glucuronides (Fig. 2B).
Some of the glucuronides transported by ABCC2
were identified in our previous work on ABCC3 (9);
these include secoisolariciresinol-glucuronide
(SECO-GlcA), enterodiol-glucuronide (END-GlcA)
and enterolactone-glucuronide (ENL-GlcA). Also
many glucuronides of unknown nature, having m/z
ratios of 557 [retention time (rt) 16 –16.5 min, 2
peaks], 553 (rt 17.5 min), 445 (rt 18 min), 461 (rt
18.5 min), 505 (rt 18.5–20.5, 2 peaks) 507 (rt 22–24,
3 peaks), and 491 (rt 27 min) were transported avidly
by ABCC2. Transport of these ABCC2 substrates was time
dependent and required ATP, as virtually no glucuronides
were taken up in the absence of ATP (Fig. 2D).
Urine is a complex body fluid containing a myriad
of compounds and will also contain (competitive)
inhibitors of ABCC2. Compounds with m/z ratios of
507 and 491 were therefore also tested in vesicular
transport experiments after their partial purification
from urine by HPLC. This approach resulted in an
increase of their ABCC2-mediated transport (Fig. 3).
We attribute this increase to a reduction of compe-
tition by other substrates present in urine and our
ability to add higher concentrations of the partially
purified compounds to the vesicles.
Figure 2. Transport of unknown ABCC2 sub-
strates present in urine in vesicular transport ex-
periments. A, B) ABCC2-containing (A) or control
(B) inside-out membrane vesicles were incubated
with an SPE extract of urine of female Abcc2/
mice for 10 min at 37°C in the presence of 4 mM
ATP, and the vesicle content was subsequently
analyzed by an LC/MS based targeted-metabolo-
mics screen. Every color represents the chromato-
gram of a specific mass transition in which 176 Da
(the glucuronic acid moiety) was lost after fragmentation. C) Chromatogram of an aliquot of the urinary SPE extract used in the
experiments shown in panels A and B. 1) m/z 557. 2) Secoisolariciresinol-glucuronide (SECO-GlcA). 3) m/z 553. 4) Enterodiol-
glucuronide (END-GlcA). 5) m/z 445 (rt 18 min). 6) m/z 461. 7) m/z 505 (rt 18.5 min). 8) Enterolactone-glucuronide (ENL-GlcA).
9) m/z 505 (rt 20.5 min). 10) m/z 507 (rt 22.8 min). 11) m/z 507 (rt 23.5 min). 12) m/z 507 (rt 23.8 min). 13) m/z 491.
D) Time-dependent transport of several glucuronides from female Abcc2/ urine into ABCC2-containing (circles) or control
(squares) Sf9 membrane vesicles. Transport into ABCC2-containing vesicles was also determined in the absence of 4 mM ATP (open
circles). For several compounds, the lines representing transport in control vesicles and in ABCC2-containing vesicles in the absence
of ATP overlap, and are therefore not visible separately. Values are presented as means  sd of triplicate (Sf9-ABCC2 ATP) or
duplicate values (Sf9-ABCC2 no ATP and Sf9-controlATP). D) Numbers between brackets above each graph correspond to the peak
numbers presented in the chromatograms.
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Identification of some of the unknown glucuronides
found to be transported by ABCC2
Many glucuronides transported by ABCC2 from Abcc2/
urine were of unknown nature. The only information we
had about these compounds was their nominal mass and the
presence of a glucuronic acid group. Fragmentation spectra
of the unknown glucuronides with m/z ratios of 557 and 553
both showed losses of neutral fragments of 176 Da (the
glucuronic acid moiety) and 80 Da, indicating the loss of a
sulfate group (ref. 14; insets inFig. 4A,C, respectively). Based
on the nominal mass, knowledge of the composition of the
mouse diet, fragmentation spectra of these unknown com-
pounds, and our previous experience with the fragmenta-
tion spectra of phytoestrogen-glucuronides, we hypothesized
that the unknown glucuronides with m/z ratios of 557 and
553 were sulfo-enterodiol-glucuronide (sulfo-END-GlcA)
and sulfo-enterolactone-glucuronide (sulfo-ENL-GlcA), re-
spectively. To verify this tentative identification, we enzymat-
ically generated these diconjugates from their respective
aglycons for identification. The chromatogram of in vitro
generated sulfo-END-GlcA is shown in Fig. 4B (for clarity,
only the MRM tracer for the mass transition 557/381 is
shown). The retention time and fragmentation spectrum
matched that of the unknown glucuronide with m/z 557 in
mouse urine. In addition, both chromatograms showed 2
peaks (albeit the intensity of the first peak had a much lower
relative abundance in Abcc2/ mouse urine). We attribute
these 2 peaks to 2 different glucuronosyl-sulfo-conjugates of
END that can be formed due to the presence of 2 phenolic
hydroxyl groups. These data unambiguously identify this
compound as sulfo-END-GlcA. By the same procedure we
identified the glucuronide with an m/z ratio of 553 as
sulfo-ENL-GlcA (Fig. 4C, D).
The identification of the glucuronides with m/z
ratios of 491 and 507 was initially unsuccessful, as their
fragmentation spectra were not informative. The pres-
ence of these compounds in urine depended on the
bedding material present in the mouse cages (see
Supplementlal Data and Supplemental Fig. S1). Their
precursors must therefore be present in the wood
shavings of the tree Picea abies, used to prepare the
bedding material. Accurate masses of the compounds
with m/z 491and 507 are given in Supplemental Table
S2. The exact nature of the glucuronides with m/z
ratios of 445 (rt 18) and 461 (rt 18.5) is currently
unknown. Both compounds were absent in urine of
Abcc2/ mice given an AIN 93G diet, which contains
virtually no phytoestrogens (data not shown).
Determination of the relative abundance of the
(unknown) glucuronides in urine of wild-type and
Abcc2/ mice
ABCC2 is present at the apical membrane of the cells in
which it is expressed and reduces the abundance of its
Figure 3. Transport of HPLC-fractionated unknown ABCC2 substrates present in Abcc2/ urine in vesicular transport
experiments. ABCC2-containing (A, D) or control (B, E) inside-out membrane vesicles were incubated with HPLC-separated
fractions of Abcc2/ urine and incubated for 10 min at 37°C in the presence of 4 mM ATP and subsequently analyzed by an
LC/MS based targeted-metabolomics screen. A, B) HPLC-purified fraction containing unknown glucuronides with an m/z ratio
of 507 was used as substrate. C) Chromatogram of this fraction. D, E) HPLC-purified fraction containing an unknown
glucuronide with m/z 491 was used as substrate matrix. F) Chromatogram of this fraction. Insets: time-dependent transport of
the glucuronides of interest into ABCC2-containing (circles) or control (squares) Sf9 membrane vesicles. Transport was
determined in the presence (closed symbols) or absence (open symbols) of 4 mM ATP. Note that lines representing transport
in control vesicles and in ABCC2-containing vesicles in the absence of ATP overlap and are therefore not visible separately.
Values are presented as means  sd of an experiment performed in triplicate. See Fig. 2 for identity of peak numbers in
chromatograms and above insets.
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substrates in plasma and subsequently in urine (1).
Compared to wild-type mice, Abcc2/ mice should
therefore have higher levels of ABCC2 substrates in
their urine. This condition was indeed what we found:
Sulfo-END-GlcA, sulfo-ENL-GlcA, SECO-GlcA, the P.
abies-associated glucuronides and the unknown gluc-
uronide with an m/z ratio 461 were all more abundant
in urine of Abcc2/ mice than of wild-type mice
(Fig. 5A, B). Only urine levels of END-GlcA and ENL-
GlcA, which were found to be well transported by
Figure 5. Relative concentration of selected glucuronides, several of unknown nature, in urine of wild-type and Abcc2/ mice.
A, B) Urine samples of a wild-type (A) and an Abcc2/ (B) mouse were analyzed by LC/MS/MS for the relative abundance of
several glucuronides. Every color represents the chromatogram of a specific mass transition in which 176 Da (the glucuronic
acid moiety) was lost after fragmentation. See Fig. 2 for identify of peak numbers 1–13; 14	 genistein-glucuronide (GEN-GlcA).
C) Relative quantification of several of the glucuronides in urine of wild-type and Abcc2/ mice (n	4 or 5). Numbers between
brackets above each graph correspond to the peak numbers presented within the chromatograms. Data are presented as
means  sd.
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Figure 4. Identification of several of the unknown glucuronides in plasma and
urine that are more abundant in the absence of ABCC2. Urine samples of
Abcc2/ mice and in vitro generated enterolignan metabolites were analyzed by
LC/MS employing information-dependent acquisition to generate fragmenta-
tion spectra (insets). A, B) Chromatograms of the MRM tracer for the unknown
glucuronide with an m/z ratio of 557 in urine of an Abcc2/ mouse (A) and in
vitro generated sulfo-END-glucuronide (B). C, D) Chromatograms of the MRM
tracer for the unknown glucuronide with an m/z ratio of 553 in Abcc2/ urine
(C) and in vitro generated sulfo-ENL-glucuronide (D).
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ABCC2 from Abcc2/ urine, were not affected greatly
by the absence of ABCC2 (Fig. 5C). Although initially
we did not detect genistein-glucuronide (GEN-GlcA) in
ABCC2-containing vesicles, this compound was more
abundant in urine of Abcc2/ mice than of wild-type
mice. Closer inspection of the chromatograms ob-
tained with ABCC2-containing vesicles incubated for 10
min in Abcc2/ urine revealed that low amounts of
GEN-GlcA were present, which resulted in a signal that
was only just above the limit of detection of the assay.
These data fit those of Jager et al. (15), who found that
a defect in ABCC2 in rats impairs biliary excretion of
GEN-GlcA and, hence, more can be expected to be
excreted in the urine. Figure 5C also shows that several
glucuronides were more abundant in female than in
male urine, as we have seen before (9). Especially the
compounds with m/z ratios of 491 and 507 were
predominantly present in urine of female Abcc2/
mice.
Determination of the relative abundance of the
unknown glucuronides in bile of wild-type and
Abcc2/ mice
An important function of ABCC2 lies in the transport
of its substrates into bile, directing them for fecal
excretion (12). This finding led us to apply the LC/
MS-based glucuronide screen to bile samples of male
wild-type and Abcc2/ mice (Fig. 6). As expected, bile
contained many compounds conjugated to glucuronic
acid. The abundance of SECO-GlcA, and especially
sulfo-ENL-GlcA and sulfo-END-GlcA, were reduced in
bile of Abcc2/ mice. Concentrations of END-GlcA
and ENL-GlcA were also clearly reduced in bile of
Abcc2/ mice (compare Fig. 6A, B), whereas levels of
these glucuronides in urine were unaltered by the
absence of ABCC2. We found the opposite for the
unknown glucuronides with m/z ratios of 491 and 507:
absence of ABCC2 led to up to 20-fold higher urine
levels but had no effect on bile concentrations. Biliary
levels of GEN-GlcA and the glucuronide with m/z 461
were below the detection limit of the assay.
Determination of the kinetic parameters of
ABCC2-mediated transport of sulfo-END-GlcA and
sulfo-ENL-GlcA
To determine the transport kinetics for the identified
divalent substrates, we enzymatically synthesized the
diconjugates sulfo-END-GlcA and sulfo-ENL-GlcA for
use in vesicular transport experiments. ABCC2-con-
taining vesicles transported these substrates in a time-
and ATP-dependent manner, with virtually no trans-
port found in control vesicles (Fig. 7A, B). Transport
Figure 6. Relative concentration of selected glucuronides, several of unknown nature, in bile of wild-type and Abcc2/ mice.
A, B) Bile samples of a wild-type (A) and an Abcc2/ (B) mouse were analyzed by LC/MS/MS for the relative abundance of
several glucuronides. Every color represents the chromatogram of a specific mass transition in which 176 Da (the glucuronic
acid moiety) was lost after fragmentation. See Fig. 2 for identity of peak numbers. C) Determination of the peak areas (a measure
of their relative abundance) of selected glucuronides in bile of wild-type and Abcc2/ mice (n	5). Numbers between brackets
above each graph correspond to peak numbers in chromatograms. Data are presented as means  sd.
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followed Michaelis-Menten kinetics (Fig. 7C, D).
Nonlinear regression analysis yielded Km values of
0.75  0.1 and 0.6  0.1 M for sulfo-END-GlcA and
sulfo-ENL-GlcA, respectively (Fig. 7C, D), showing
that these divalent anions are high-affinity ABCC2
substrates.
DISCUSSION
Vesicular transport experiments are widely used to
study ABC transporters (16). Radioactive substrates are
preferred in these experiments due to the easy detec-
tion of substrates inside the vesicles by liquid scintilla-
tion counting (LSC). Other detection methods have
recently gained some popularity (17, 18) but are still
only scarcely used. We now show that incubation of
ABCC2-containing inside-out vesicles in urine leads to
the intravesicular accumulation of many (often un-
known) ABCC2 substrates, which can easily be detected
by LC/MS-based metabolomics screens. The reason for
using Abcc2/ mouse urine for these screens was a
trivial one: Urine is relatively easily obtained, and we
expected that Abcc2/ urine would contain the highest
concentration of ABCC2 substrates. The concentration
of the glucuronic acid conjugates in urine was not a
limiting factor for their detection in ABCC2-containing
vesicles, however, as we used 100-fold diluted Abcc2/
urine in these experiments.
For two of the substrates identified, sulfo-END-GlcA
and sulfo-ENL-GlcA, we determined transport kinetics
and these divalent metabolites proved to be high-
affinity substrates, indicating that ABCC2 has a prefer-
ence for divalent anions. This finding fits well with data
from Oude Elferink et al. (19), who found that divalent
bile acids were strong competitive inhibitors of ABCC2-
mediated transport, whereas monovalent bile acids
were less potent.
We expect that transportomics has great potential
and are exploring whether other body fluids and tissue
extracts, including plasma and urine of humans, can be
used in vesicular transport experiments as well. This
could reduce the number of experimental animals
required to find the physiological substrates of various
ABC transporters. It also means that identification of
compounds is not a prerequisite to study their trans-
port in vesicular transport experiments, as one can fish
for new substrates. The potential of transportomics can
be extended by developing targeted metabolomics
screens detecting compounds conjugated to sulfate or
glutathione, other classes of phase II metabolites with a
very specific fragmentation spectrum during CID (14,
20). Untargeted metabolomic analyses of the vesicle
content would further increase the range of potential
substrates identified. The method can be applied to
other ATP-dependent transporters as well, including
ABCCs for which no knockout mouse models are
available (ABCC11 and ABCC12). The ability to directly
test the substrates transported by the human trans-
porter orthologue is also an important advantage.
Also, there are disadvantages associated with this
Figure 7. Transport of enterolignans conjugated to glucuronic acid and sulfate
by ABCC2 in vesicular transport experiments. ABCC2-containing (circles) or
control (squares) membrane vesicles were incubated at 37°C in the presence of
4 mM ATP (solid symbols) or without ATP (open symbols). A, B) Time-
dependent transport of [35S]sulfo-enterodiol-glucuronide (11 pM; A) and
[35S]sulfo-enterolactone-glucuronide (344 pM; B). Note that lines representing
transport in control vesicles and in ABCC2-containing vesicles in the absence of
ATP overlap and are therefore not separately visible. C, D) Concentration-
dependent transport of [35S]sulfo-enterodiol-glucuronide (C) and [35S]sulfo-
enterolactone-glucuronide (D). Vesicles were incubated for 30 s; values are
corrected for transport in the absence of ATP. Values are presented as means 
sd of triplicate (ATP) or duplicate values (no ATP).
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method. Transportomics is probably less suitable to
finding hydrophobic substrates, which will partition in
the vesicle membrane and/or diffuse out of the vesicles
and escape detection. The detection of radioactive
substrates with LSC is more sensitive than detection of
nonradioactive compounds by LC/MS. However, the
rapid technological advances within the field of mass
spectrometry will make detection of substrates by
LC/MS increasingly competitive. Body fluids are gen-
erally complex and will often also contain (competi-
tive) inhibitors of the transporter of interest. These
inhibitors could mask transport of some substrates (an
example is the amount of GEN-GlcA detected in
ABCC2-containing vesicles after incubation in Abcc2/
urine). This disadvantage can be partly overcome by
fractionation of the body fluid, for instance, by HPLC
(e.g., see Fig. 3). In vesicular transport experiments
often many samples are generated. Due to the long
LC/MS analysis time needed per sample, the technique
places a burden on (expensive) LC/MS equipment.
New Ultra-HPLC (UHPLC) techniques partly over-
come this disadvantage by considerably shortening the
analysis time, without losing chromatographic resolu-
tion (21). Also, it is difficult to determine the kinetic
parameters of transport.
All new ABCC2 substrates identified in this study are
phase II metabolites of phytoestrogens, compounds
that weakly interact with estrogen receptors and that
can exert estrogenic or antiestrogenic effects (22).
END, ENL, and SECO are enterolignans, whereas GEN
is an isoflavone (22). The glucuronides with m/z ratios
of 491 and 507 could be identified as glucuronides of
xenobiotics present in the tree P. abies (Supplemental
Fig. S1), further stressing the importance of ABCC2 in
the disposition of plant-derived xenobiotics.
Glucuronidation and sulfo-conjugation convert xe-
nobiotics like phytoestrogens into less active but more
hydrophilic metabolites (22) that need specific trans-
porters to leave the cell. Our current data show that
ABCC2 is one of these transporters just like ABCC3 (9).
The broad array of detoxification systems and associ-
ated transporters that deal with phytoestrogens and
their metabolites suggests that it is crucial to quickly
inactivate and dispose of phytoestrogens, which might
otherwise interfere with the hormonal balance of mam-
mals by their interaction with estrogen receptors.
ABCC2 transports its substrates over the apical mem-
brane of hepatocytes, enterocytes, and the cells of the
proximal tubule in the kidney (2, 3, 23, 24). As a
consequence, ABCC2 reduces the concentration of its
substrates in the circulation and urine, whereas it
increases the abundance of its substrates in bile. END
and ENL are formed by resident bacteria in the colon
from a lignan precursor molecule (25), and glucuroni-
dated by the enterocytes of the colon, from where they
are transported by ABCC3 over the basolateral mem-
brane toward plasma for urinary excretion (9). ABCC2
is not expressed in the large intestine (26), which
explains why no dramatic effect on urine levels of
END-GlcA and ENL-GlcA was found in the absence of
ABCC2. Some circulating END-GlcA and ENL-GlcA will
be taken up by the liver and partly transported into bile
by ABCC2 in wild-type mice. This process is missing in
Abcc2/ mice, resulting in lower levels of END-GlcA
and ENL-GlcA in Abcc2/ bile and an increase in the
fraction transported by ABCC3 over the sinusoidal
membrane (9) into the blood circulation and subse-
quently excreted via urine.
Urine levels of several other compounds, including
SECO-GlcA, GEN-GlcA, and the P. abies-derived gluc-
uronides, were highly dependent on ABCC2 activity,
whereas their levels in bile were not. Two processes
might contribute to these results. First, the aglycones of
these glucuronides are absorbed in the small intestine
where they are conjugated to glucuronic acid and
transported over the apical membrane by ABCC2 to-
ward the gut lumen in wild-type mice. In Abcc2/ mice
this does not occur, and the glucuronides are trans-
ported over the basolateral membrane into the blood
circulation by ABCC3 resulting in urinary excretion.
Second, due to the impaired biliary excretion of these
glucuronides, their concentration in hepatocytes will
rise. This finding might allow low-affinity transporters
to compensate for the lack of ABCC2, which resulted in
similar amounts of these compounds being transported
into bile as in wild-type mice.
In summary, we have established a new technique
using ABCC2 vesicles to extract ABCC2 substrates from
body fluids. This technique has allowed us to show that
ABCC2 has an important role in the disposition of a
wide range of plant-derived xenobiotics by directing
them toward fecal excretion.
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